There are currently 48 active clinical trials seeking participants for Solid Tumors research studies. The states with the highest number of trials for Solid Tumors participants are Texas, California, New York and Tennessee.
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06179160
Recruiting
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Mayo Clinic Hospital, Phoenix, Arizona +19 locations
Conditions: Solid Tumors
Register for Updates
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873
Recruiting
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the par... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: University of Arizona Cancer Center ( Site 0018), Tucson, Arizona +543 locations
Conditions: Solid Tumors, Hematologic Malignancies
Register for Updates
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
NCT05387265
Recruiting
The purpose of this first-in-human study, CTMX-904-101, is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-904 in adult subjects with metastatic or locally advanced unresectable solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Sarah Cannon Research Institute at HealthONE, Denver, Colorado +4 locations
Conditions: Solid Tumors
Register for Updates
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
NCT06158958
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy and in combination with budigalimab, (ABBV-181). ABBV-303 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-303 as a single agent or in combination with bud... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: City of Hope /ID# 254303, Duarte, California +16 locations
Conditions: Solid Tumors
Register for Updates
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
NCT03366116
Recruiting
Background: Blood, tissue, and tumor cells contain genes. Genes are made up of DNA. DNA is the instruction book for each cell. In some people with cancer, the genes that might have slowed the growth of their tumor were turned off. Researchers want to see if a new drug can turn the genes back on and slow the tumor growth. The drug is called Aza-TdC. Objective: To test the safety of Aza-TdC, and to find out the dose of this drug that can be safely given to humans. Eligibility: People ages 18... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
06/13/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms, Solid Tumors
Register for Updates
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
NCT04140500
Recruiting
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with advanced and/or metastatic solid tumors. This study aims to establish the maximum tolerated dose (MTD) and/or define the recommended phase 2 dose (RP2D) based on the safety, tolerability, pharmacokinetic (PK) and/or pharmacodynamic (PD) profile of RO7247669, and to evaluat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Sharp Memorial Hospital, San Diego, California +33 locations
Conditions: Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
Register for Updates
A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors)
NCT05155332
Recruiting
This study is open to adults with different types of advanced cancer (solid tumors) that are accessible for injection and/or biopsy. This study is for people for whom previous treatment was not successful or no treatment exists. The purpose of this study is to find the highest dose of a medicine called BI 1831169 that people with advanced cancer can tolerate when taken with or without ezabenlimab. Another purpose is to see whether BI 1831169 can fight cancer. BI 1831169 and ezabenlimab are medic... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Providence St. John's Health Center, Santa Monica, California +16 locations
Conditions: Solid Tumors
Register for Updates
A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer
NCT05839600
Recruiting
This study is open to adults with advanced solid tumours. People with solid tumours for whom previous treatment was not successful or no treatment exists can take part. The purpose of this study is to find the highest dose of a medicine called BI 1821736 that people with advanced solid tumours can tolerate. BI 1821736 is a type of immunotherapy. It is a special virus that kills cancer cells and helps the immune system fight cancer. In this study, BI 1821736 is given to humans for the first time... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Yale Cancer Center, New Haven, Connecticut +8 locations
Conditions: Solid Tumors
Register for Updates
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
NCT05512377
Recruiting
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists. The purpose of this study is to find out whether a medicine called BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. All participants take BI 907828 as a tablet once every 3 weeks. Part... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Southern Cancer Center, Mobile, Alabama +64 locations
Conditions: Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms, Bladder Cancer
Register for Updates
Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors
NCT02379416
Recruiting
Background: - Researchers want to find better ways to treat cancer. One drug that treats cancer is paclitaxel. Sometimes proteins block that drug from working. Researchers want to see if another drug, nilotinib, helps paclitaxel work better. Objective: - To test the safety of nilotinib plus paclitaxel and find out what doses of the drugs can be given safely to people. Eligibility: - Adults at least 18 years old with advanced cancer that has progressed after receiving standard treatment, or... Read More
Gender:
All
Ages:
Between 12 years and 120 years
Trial Updated:
06/08/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Solid Tumors
Register for Updates
A Study of IBI363 in Subjects With Advanced Solid Malignancies
NCT06281678
Recruiting
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Oncology Consultants P.A., Houston, Texas
Conditions: Solid Tumors
Register for Updates
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845
Recruiting
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors... Read More
Gender:
All
Ages:
All
Trial Updated:
06/05/2024
Locations: Southern Cancer Center, Daphne, Alabama +169 locations
Conditions: Solid Tumors
Register for Updates